-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60

Benzinga·11/10/2026 15:53:42
Listen to the news
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.